<PAGE>
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
SEC File No:
NOTIFICATION OF LATE FILING 0-12968
Form 10-K or 10-KSB
For Period Ended December 31, 1995
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
Not applicable. The filing relates to the
entire Form 10-K or 10-KSB.
PART I--REGISTRANT INFORMATION
Full Name of Registrant: INMEDICA DEVELOPMENT CORPORATION
Address of Principal Executive Office:
495 East 4500 South, Suite 230
City, State and Zip Code: Salt Lake City, Utah 84107
PART II--RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report or semi-annual report/portion thereof
will be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report/portion thereof will be
filed on or before the fifth calendar day following the prescribed due date;
and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
1
<PAGE>
PART III--NARRATIVE
State below in reasonable detail the reasons why Form 10-K or 10-KSB or
portion thereof could not be filed within the prescribed time period.
The reason the report could not be timely filed is that
the Company had an unusual number of significant
developments during the year and additional time was
necessary to analyze this information. The Company is
also finalizing offers to eliminate certain debenture
debt. During the period of the extension, the Company
may receive information to report regarding the status
of the offers to eliminate debt and be able to make
disclosure of any developments regarding the same.
PART IV--OTHER INFORMATION
(1) The person to contact in regard to this notification is:
Scott R. Jenkins (801) 531-8300
(2) Have all other periodic reports required under section 13 or 15(d)
of the Securities Exchange Act of 1934 or section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof? [X] Yes [ ] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of results cannot be made.
The Company expects to report gross revenues of approximately $690,000
for the year ended 12/31/95 as compared to $650,000 for the prior year, which
had included five quarters of royalty revenues compared with four quarters
for the 1995 year. The Company's general and administrative expense is
expected to increase by approximately $55,000 for the 1995 year when compared
to the 1994 year and research and development expense is expected to increase
by approximately $200,000 for 1995 as compared to 1994. Notwithstanding the
increase in expenses, due to the increase in revenues and to extraordinary
gain of about $200,000, the Company's net income is expected to increase by
about $30,000 for 1995 when compared to 1994.
2
<PAGE>
INMEDICA DEVELOPMENT CORPORATION
has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: March 29, 1996 By: /s/ Richard Bruggeman
----------------------------
Richard Bruggeman, Secretary
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title
of the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant by an
authorized representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
3
